IDIX has initiated a Phase II clinical trial evaluating IDX184+ SoC for 14 days and doses of up to 200mg (Patients will continue on treatment with pegylated interferon and ribavirin for 14 more days):
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.